Epacadostat is currently being tested in clinical trials in 14 tumor types (including the above cancers) with co-administration of anti-PD-1 antibodies (nivolumab or pembrolizumab) or anti-PD-L1 antibodies (atezolizumab and durvalumab). This evidence concerns the gene PDCD1 and neoplasm.